Publications

Bhutani, D. et al. Long term follow-up of patients with AL amyloidosis treated on a phase 1 study of Anti-Amyloid Monoclonal Antibody CAEL-101. Virtual International Symposium on Amyloidosis (ISA), September 14 to 18, 2020. Abstract 342.

Bhutani, D. et al. Improvement in Global Longitudinal Strain (GLS) Correlates with NT-ProBNP Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid mAb CAEL-101. 60th Annual American Society of Hematology; 2018. Abstract 958.

Fu, J. et al. Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Chimeric Antibody CAEL-101.  60th Annual American Society of Hematology; 2018. Abstract 1003.

Fu, J. et al. Real-Time PET Imaging with Amyloid Fibril-Reactive Antibody CAEL-101 for Personalized AL Amyloidosis Immunotherapy. The International Myeloma Workshop; 2019. Poster SP-190.

Edwards, C. et al. Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody11-1F4 (CAEL-101) in Patients with AL Amyloidosis.  16th International Symposium on Amyloidosis (ISA); 2018.

Edwards, C. et al. Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody 11-1F4 (CAEL-101) in Patients with AL Amyloidosis. 59th Annual American Society of Hematology; 2017. Abstract 509.

Edwards, C. et al. Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. 58th Annual American Society of Hematology; December 2016. Abstract 643.

Hrncic R, Wall JS, et al. Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits. Am J Pathol 2000; 157(4): 1239-1246.

Khouri, J, et al. Safety, Tolerability and Efficacy of CAEL-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients with AL Amyloidosis. 62nd Annual American Society of Hematology; December 2020. Abstract 729. View Presentation. Listen to Replay of the Presentation

Langer, A, et al. Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. 57^th Annual American Society of Hematology; December 2015. Abstract 188.

O’Nuallain B, et al. Phage Display and Peptide Mapping of an Immunoglobulin Light Chain Fibril-Related Conformational Epitope. Biochemistry 2007; 46(45): 1349-58.

O’Nuallain B, et al. Localization of a Conformational Epitope Common to Non-Native and Fibrillar Immunoglobulin Light Chains. Biochemistry 2007; 46(5): 1240-1247.

Solomon A, Weiss DT, Wall, JS. Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid Reactive Monoclonal Antibodies. Cancer Biother Radiopharm 2003; 18(6): 853-60.

Valent, J, et al. CAEL-101 is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphomide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144). 62nd Annual American Society of Hematology; December 2020. Abstract 2277. View Poster Presentation. Watch the Video.

Valent, J. et al. Safety and Tolerability of CAEL-101 in Combination With Cyclophosphamide-Bortezomib-Dexamethasone and Daratumumab in Patients With AL Amyloidosis and Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis In a Phase 2 Study for a Median of 49 Weeks. European Hematology Association 2021. June 2021. eposters 1017 and 1018.

Wall JS, Kennel SJ, et al. Radioimaging of Light Chain Amyloid with a Fibril Reactive Monoclonal Antibody. J Nucl Med 2006; 47(12): 2016-2024.

Wall JS, Solomon A, Kennel SJ. Development and Evaluation of Agents for Targeting Visceral Amyloid. Tijdschr Nucl Geneeskd 2011; 33(4): 807-814.

Wall JS, et al. Radioimmunodetection of Amyloid Deposits in Patients with AL Amyloidosis. Blood 2010; 116(13): 2241-4.